Filing Details

Accession Number:
0001127602-20-021823
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-07-20 16:53:12
Reporting Period:
2020-07-17
Accepted Time:
2020-07-20 16:53:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
310158 Merck & Co. Inc. MRK Pharmaceutical Preparations (2834) 221918501
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1628884 L. Julie Gerberding Merck & Co., Inc.
2000 Galloping Hill Road
Kenilworth NJ 07033
Evp Strat Comm, Gi Pub Policy No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-07-17 18,111 $0.00 62,862 No 4 M Direct
Common Stock Disposition 2020-07-17 18,111 $80.00 44,751 No 4 S Direct
Common Stock Disposition 2020-07-17 18,174 $80.01 26,577 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-07-17 18,111 $0.00 18,111 $54.68
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2017-05-10 2026-05-09 No 4 M Direct
Footnotes
  1. The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.0000 to $80.0450, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
  3. Holdings include shares acquired in dividend reinvestment transactions.
  4. The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.